Synergistic ophthalmological composition in a low-concentration dose that is effective in the prevention, control and eradication of presbyopia

A pharmaceutical composition for ophthalmic administration for use in the prevention, control, and treatment of the symptoms of presbyopia and to improve near vision ability and increase the depth of focus in the patient's eyes, comprising the synergistic combination of:

• i. One or more cholinergic agonist agents or their racemic forms or pharmaceutically acceptable salts thereof, preferably selected from pilocarpine
• ii. One or more alpha 1-adrenergic agonist agents or their racemic forms or their pharmaceutically acceptable salts, preferably selected from oxymetazoline
• ii. One or more alpha 2-adrenergic agonist agents or their racemic forms or their pharmaceutically acceptable salts, preferably selected from brimonidine
• iv. One or more glycosaminoglucuronan agents or their racemic forms or their pharmaceutically acceptable salts, selected preferably from hyaluronic acid
• v. One or more non-steroidal anti-inflammatory agents or their racemic forms or pharmaceutically acceptable salts thereof, selected from bromfenac
• vi. One or more vasoconstrictor agents or their racemic forms or their pharmaceutically acceptable salts, preferably selected from oxymetazoline, phenylephrine, tetrahydrozoline and naphazoline
• vii. A pharmaceutically acceptable vehicle, adjuvant, or excipient.